Matthew R. Kudelka

Matthew R. Kudelka

Auto-generated profile, based on publicly available information

Matthew R. Kudelka

Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJunwei Zeng
Junwei Zeng
MEMahmoud Eljalby
Mahmoud Eljalby
RARajindra Aryal
Rajindra Aryal
SLSylvain Lehoux
Sylvain Lehoux
KSKathrin Stavenhagen
Kathrin Stavenhagen
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
The molecular mechanisms regulating lymphocyte homing into lymph nodes are only partly understood. Here, we report that B cell-specific deletion of the X-linked gene,Cosmc, and the consequent decrease of protein O-glycosylation, induces developmental blocks of mouse B cells. After transfer into wild-type recipient,Cosmc-null B cells fail to home to lymph nodes as well as non-lymphoid organs. Enzymatic desialylation of wild-type B cells blocks their migration into lymph nodes, indicating a requirement of sialylated O-glycans for proper trafficking. Mechanistically,Cosmc-deficient B cells have normal rolling and firm arrest on high endothelium venules (HEV), thereby attributing their inefficient trafficking to alterations in the subsequent transendothelial migration step. Finally,Cosmc-null B cells have defective chemokine signaling responses. Our results thus demonstrate thatCosmcand its effects on O-glycosylation are important for controlling B cell homing.

1 April 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
Diane ParkDiane Park
Diane Park
JCJiaxuan Chen
Jiaxuan Chen
MKMatthew R. Kudelka
Matthew R. Kudelka
NJNan Jia
Nan Jia
CHCarolyn A. Haller
Carolyn A. Haller
ECElliot L. Chaikof
Elliot L. Chaikof

12 August 2025 in Glycobiology
Verified
Journal Article
Open access
PKPascal B Kunz
Pascal B Kunz
ETEa Kristine Clarisse Tulin
Ea Kristine Clarisse Tulin
AMAkul Mehta
Akul Mehta
TJTianwei Jia
Tianwei Jia
JHJamie Heimburg-Molinaro
Jamie Heimburg-Molinaro
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
A major challenge in the glycosciences is the scarcity of sensitive and specific glycan-binding reagents, such as monoclonal antibodies, for detecting and isolating glycans. Here we report the development and characterization of new monoclonal antibodies (mAbs) that bind carbohydrate-based red blood cell (RBC) antigens including the ABO(H) antigens. This approach exploits the immune system of the sea lamprey (Petromyzon marinus), which strongly responds to human glycans to enable the generation of high affinity antibodies. To develop these mAbs, we immunized the lamprey with RBCs and designed a targeted antibody enrichment and screening process using intact RBCs and a custom microarray displaying blood group antigens. Through multiple rounds of enrichment and testing we identified two mAbs; A_25 and A_39. Glycan binding analysis of the mAbs using glycan microarrays, the Luminex platform and western blot analysis revealed their binding to H antigens and terminal N-acetyllactosamine Galβ1-4GlcNAc (LacNAc, a type 2 sequence). Mechanistic insights into antigen specificity were gained through glycan inhibition assays, sequence homology analysis, and nanomolar-range affinity measurements. mAb binding to RBCs was determined using flow cytometry. Both mAbs bound RBCs of all ABO blood groups, whereas strongest binding was observed for blood group O RBCs. Our findings highlight the efficacy of the lamprey system to develop glycan-specific mAbs. These reagents allow investigation of expression of the H antigen and LacNAc-containing glycans in human tissues. In the future, they could also be modified using molecular engineering techniques to generate mAbs specific to other understudied blood group antigens.

25 February 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TJTongzhong Ju
Tongzhong Ju
YWYingchun Wang
Yingchun Wang
HNHikaru Nishio
Hikaru Nishio
MKMatthew R. Kudelka
Matthew R. Kudelka
XSXiaodong Sun
Xiaodong Sun
Richard D. CummingsRichard D. Cummings
Richard D. Cummings
Intestinal mucins have extended O-glycans comprised primarily of the common Core 1 O-glycan (Galβ1-3GalNAcα1-Ser/Thr/Tyr) and its modifications. Expression of such glycans is under control of Cosmc (C1GalT1C1) that encodes a key ER molecular chaperone required for formation of active T-synthase, a Golgi enzyme that modifies the Tn antigen (GalNAcα1-Ser/Thr/Tyr - CD175) to generate a Core 1 O-glycan. We previously observed that targeted deletion of Cosmc in murine intestinal epithelial cells (IEC-Cosmc-KO mice) resulted in dysbiosis and alteration of the microbiome. Here we report a detailed description of these mutant mice and find that IEC-Cosmc-KO mice, but not WT mice, express CD175 throughout the intestinal epithelia. CD175 expression is accompanied by loss of glycocalyx, shortening of microvilli, compromised MUC2, thickening of the epithelial layer, as well as generation of high levels of reactive oxygen species. The majority of IEC-Cosmc-/y mice beginning at ∼3 to 9 months spontaneously developed colorectal adenocarcinomas, some with invasive features evidenced by mesenteric metastases, which were potentially associated with activation of TGFβ signaling. Thus, deletion of Cosmc results in expression of CD175 and loss of extended O-glycans in IEC, which is associated with dysregulation of epithelial cell surfaces, leading to spontaneous tumor development.